Project Grant R01AI205724
Award Date 8/5/26
Completion Date 7/31/31
Dollars Obligated $856K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $297,000 to Texas Biomedical Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on targeting super-enhancers to regulate HIV transcription and latency. The project, identified as R21AI203697, will define molecular mechanisms by which super-enhancer-associated long non-coding RNAs (SE-lncRNAs) regulate HIV transcription and maintain viral latency in...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of convergent RNA polymerase II transcription in HIV-1 latency and reactivation. The research aims to define how convergent POL II transcription—specifically antisense and downstream forms originating from the 5'-LTR—regulates sense HIV-1 transcription...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Medical Branch at Galveston $294,150 on August 1, 2026, for research on defective pro-viruses and viral proteins in neuroHIV and HIV cure strategies under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research employs correlative microscopy (live-cell, confocal, and electron microscopy), mass spectrometry imaging, and spatial proteomic and mRNA analysis to detect, quantify, and...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $828,340 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV-1 transcription reactivation mechanisms in latent reservoir cells. The research explores the role of transcription factors and Tat protein in initiating and sustaining HIV-1 transcription reactivation, using genetic and genomic approaches to examine HIV-1...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $2,461,651 to the University of Texas Health Science Center at Houston under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 18, 2025, for a project extending through July 31, 2029. The project investigates estrogen's impact on immunoglobulin G (IgG) glycomic modulation of immunity and inflammation in people with human immunodeficiency virus (HIV) on antiretroviral...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $874,531 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model dynamic CD8+ T cell–virus interactions in post-treatment control of HIV. The project comprehensively defines mechanistic features of CD8+ T cell responses that most strongly relate to control of HIV after stopping antiretroviral therapy. Research will examine...
- The National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute $927,025 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate IL-21-IGFC therapy for enhancing pulmonary immune reconstitution and limiting viral persistence in co-infected macaques. The research addresses incomplete immune reconstitution in individuals co-infected with HIV and tuberculosis despite antiretroviral therapy, using an established...
- The National Institute of Environmental Health Sciences, part of the National Institutes of Health, awarded the University of Texas Health Science Center at Houston $200,268 on September 1, 2026, under the Medical Library Assistance program (CFDA 93.879) for Project Grant R21LM015664. The recipient will develop DEEPHIV-AOU, a multi-modal deep learning framework designed to improve HIV prevention through personalized risk assessment and intervention planning. The framework integrates four...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $253,256 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model through May 31, 2028. The project develops a preclinical platform for engineered B cell therapies aimed at creating a functional HIV cure. Scripps will determine whether immunoglobulin heavy chain...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $653,743 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test implementation strategies for integrating the JUNTOS referral network into HIV self-testing programs in South Florida. The project aims to improve clinical linkage and engagement for individuals engaging in HIV self-testing by deploying JUNTOS, an app and website that centralizes...